Drugs / RTS,S/AS01E
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04661579 | Nov 2020 → Jun 2022 | Plasmodium falciparum malaria | PATH | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RTS,S/AS01E | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04661579 ↗ |
| Modality | Vaccine | “GSK has developed a candidate vaccine against malaria caused by P. falciparum called RTS,S/AS01E.” NCT04661579 ↗ |
| Route | Intramuscular | “Participants received 3 vaccinations with malarial vaccine RTS,S/AS01E by intramuscular injection” NCT04661579 ↗ |